Significant prolonged aryl hydrocarbon receptor (AHR) activation, classically exhibited following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin, can cause a variety of undesirable toxicological effects. Novel pharmaceutical chemistries also have the potential to cause activation of AHR and consequent toxicities in pre-clinical species and man. Previous methods either employed relatively expensive and low-throughput primary hepatocyte dosing with PCR endpoint, or low resolution overexpressing reporter gene assays. We have developed, validated and applied an in vitro microtitre plate imaging-based medium throughput screening assay for the assessment of endogenous species-specific AHR activation potential via detection of induction of the surrogate transcriptional target Cytochrome P450 CYP1A1. Routine testing of pharmaceutical drug development candidate chemistries using this assay can influence the chemical design process and highlight AHR liabilities. This assay should be introduced such that human AHR activation liability is flagged early for confirmatory testing.
The aryl hydrocarbon receptor (AHR) is a cytosolic ligandactivated Per/Arnt/Sim domain-containing transcription factor (Denison and Whitlock, 1995) expressed in a broad range of cell and tissue types (Hankinson, 1995) and has a wide variety of physiological roles (Fujii-Kuriyama and Kawajiri, 2010; Schmidt et al., 1996) from ligand metabolism to cellular development. Prior to ligand binding the AHR is present within the cytoplasm, retained in complex with a variety of chaperone proteins including HSP90 (Perdew, 1988; Wilhelmsson et al., 1990) , AIP (a.k.a. XAP2, Carver and Bradfield, 1997; Ma and Whitlock, 1997) , and PTGES3 (a.k.a. p23, Kazlauskas et al., 1999; Nair et al., 1996) . Following ligand binding the AHR complex translocates into the nucleus, where it forms a heterodimer with the AHR Nuclear Translocator, and binds Xenobiotic/Dioxin Response Element (DRE) sequences within regulatory regions of a wide variety of target genes (Matsushita et al, 1993) . These target genes regulate diverse cellular functions, which critically include upregulation of phase I and II biotransformation enzymes facilitating xenobiotic metabolism including CYP1A1, CYP1A2, CYP1B1, ALDH3A1, NQO1, and UGT1A1 (Hankinson, 1995; Nebert, 1994) . These proteins can then act to remove the original activating ligand. Recent evidence has highlighted a second noncanonical AHR signaling pathway involving Kruppel-like Factor 6 (KLF6, Wilson et al., 2013) and CPS1 binding at an alternative recognition sequence (Joshi et al., 2015) .
The most studied AHR ligand is 2,3,7,8-tetrachlorodibenzop-dioxin (TCDD a.k.a. dioxin). In rodent models toxic effects of TCDD include wasting syndrome, hepatosteatosis, thymic involution, carcinogenicity and teratogenicity (Poland and Knutson, 1982) . The effects of AHR activation by accidental acute TCDD exposure in man are also well documented as leading to choloracne, disturbed endocrine homeostasis, impaired immunity and detrimental effects on cellular proliferation and tissue differentiation (Fujii-Kuriyama and Kawajiri, 2010; Hankinson, 1995; Poland and Knutson, 1982) , plus some indication of a temporarily increased incidence of cancer. Studies in AHR-knockout mice demonstrate that the toxic mechanisms of TCDD require a functional AHR (Fernandez-Salguero et al., 1996) clearly showing the toxicological significance of this receptor. It is thought that TCDD acts in this manner due to its biological intransigence (Bock, 1994) .
AHR can also be activated to a lesser extent by a chemically diverse set of compounds (Denison and Nagy, 2003) . This is exemplified by records of chloracne in individuals accidentally exposed to some drug candidate molecules or their intermediate building blocks during agrochemical or pharmaceutical development (Scerri et al., 1995; Taylor et al., 1977) , with the implication that this could have been due to activation of AHR by these chemicals. This serves to illustrate the need for improved identification of TCDD-like AHR activation liability in early pharmaceutical drug discovery and development. However it is also important to note that the majority of pharmaceuticals which induce CYP1A1, with or without AHR activation, do not exhibit TCDD-like toxicity (Hu et al., 2007) .
To find utility in early drug discovery any such method (or assay) must have sufficient throughput to be capable of testing a large number of different chemicals in a short timeframe and enable inclusion of this data together with other measures of drug candidate efficacy used to build chemical structureactivity relationships (SAR). This has led to the increasing use of in vitro molecular and cellular models which can be scaled, miniaturized and made cost efficient enough to meet these throughput requirements. Current best practice RT-PCR on, for example ex vivo primary hepatocytes (Graham and Lake, 2008) , remains too costly and low throughput to meet these requirements. Alternatives such as overexpressing reporter gene assays (Brennan et al., 2015) achieve the required throughput with sensitivities down to 0.1 qM TCDD, and also to some extent demonstrate clinically relevant species selective potency differences. However they lack resolution at the cellular level to determine mechanism of action, and with endogenous pathways being implicated in TCDD toxicity (Murray et al., 2010) these mixed systems utilizing exogenous canonical DREs could give misleading results. To impact drug development such assays should ideally be applicable in both preclinical species and the clinical setting. Here we describe a novel medium throughput in vitro method for monitoring the endogenous AHR activation potential of new chemical entities in both human and rat hepatic cell systems, and discuss the impact of this method in a pharmaceutical drug discovery setting. This method employs detection by high content imaging analysis of the upregulation of the downstream transcriptional target CYP1A1, as surrogate of AHR activation, enabling highly sensitive quantification at the single cell level. We show that use of this method can reduce drug attrition by facilitating earlier deprioritization of potentially toxic AHR activating chemistries.
MATERIALS AND METHODS
Cell culture. Cell lines were originally obtained from the European Collection of Authenticated Cell Cultures (PHE, Porton Down, UK), and all banks used were validated for contamination and viability. Manually-cultured H4-II-E c3 (20 000 cells/well) or HepG2 (20 000 cells/well) were seeded onto Packard 96-well Viewplates (PerkinElmer, Buckinghamshire, UK) or Collagen Icoated 96-well plates (Corning BD Falcon, Oxford, UK) respectively, in Roswell Park Memorial Institute media (RPMI-1640) containing 10% Foetal Calf Serum (FCS), 2 mM LGlutamine and 1% Nonessential Amino Acids (all media and supplements from Sigma-Aldrich, Dorset, UK) and allowed to recover at 37 C, 5% CO 2 , 90% relative humidity (RH) for 24 h prior to compound treatment.
Cell cryopreservation. Cells were cryopreserved in RPMI-1640 containing 7.5% Dimethylsulfoxide (DMSO) and 50% FCS. Following thawing cells were washed once in RPMI-1640 by centrifugation. H4-II-E c3 (10 000 cells/well) or HepG2 (5000 cells/well) in complete media were seeded onto Packard 96-well Viewplates or Collagen I-coated 96-well plates respectively, and allowed to recover as above for 72 h prior to compound treatment.
Compound treatment. A number of commercially available compounds were selected on the basis of previous reports of CYP1A1 induction potential in either rat or human cell systems. TCDD (99% chemical purity) was obtained from Cambridge Isotope Laboratories (CK Gas Products, Hampshire, UK) and all other compounds from Sigma-Aldrich, UK or the AstraZeneca compound collection. Compounds were dissolved in DMSO to give 1000Â stocks. Serial dilution using a MicroLab STAR liquid handling platform (Hamilton Robotics, Bonaduz, Switzerland) generated a 10-point half-log dilution series for each compound. For compound screening each assay plate also contained 8 positive (10 nM TCDD) and 8 negative control wells (0.1% final DMSO). These stocks were diluted to 50Â the final top concentration in the appropriate cell culture media. A 0.1% DMSO final concentration was maintained in all wells. Cells were exposed to compound at 37 C, 5% CO 2 , 90% RH for 24 h prior to fixation.
Antibodies. Rabbit antiRat Cyp1A1 antibody (Chemicon, Billerica, USA) and rabbit antiHuman CYP1A1/2 antibody (Cypex, Dundee, UK) were stored at À20 C until use. Antibody solutions were made up in a blocking buffer containing 1.1% Bovine serum albumin (BSA), 0.2% Triton X100 in PBS/A (Sigma-Aldrich, UK) prior to use at 1:3000 and 1:500, respectively. Quantification of fluorescence images. In order to quantify CYP1A1 protein levels, imaging algorithms were established to identify the presence of nuclei and cytoplasmic staining. Images were analysed using an in-house algorithm written in Definiens Developer software (Definiens, Munich, Germany) . Briefly, the algorithm classified nuclei based on their nuclear fluorescence intensity and morphology. The cytoplasm was then identified by a watershed algorithm for CYP1A1 fluorescence using the nuclei as seeds, and the cytoplasmic signal intensity for each individual cell was determined. This intensity was compared against a threshold value to categorize each cell as a positive or negative responder, and the proportion of positive responders in the whole well population was determined as the primary output signal.
Statistical data analysis. Individual well positive responders' proportion data was normalized to the local plate controls using:
Xnorm ¼ ðX -MedianðnegÞÞ=ðMedianðposÞ -MedianðnegÞÞ where pos ¼ 10 nM TCDD and neg ¼ 0:1% DMSO:
To identify outliers due to nonspecific cellular toxicity the nuclei count per well was correlated against the median nuclei count of the on-plate negative controls, and primary data points where this number fell below a threshold value derived from observation of known cytotoxic compounds (>60% loss for rat and >30% loss for human, data not shown) were removed from further analysis. Wells with imaging errors caused by bright artefacts or out-of-focus issues were also removed by manual image observation.
Compound data were then aggregated by concentration into individual test sample compound curves and overall compound curves. Agonist concentration-response curves were fitted using Origin (OriginLab Corp., Massachusetts, USA) to the equation: 
where d i is the difference in ranks.
RESULTS

Immunostaining of Rat and Human CYP1A1 Protein in Cell Lines
The feasibility of detecting changes in of CYP1A1 protein levels was investigated in the rat liver hepatoma cell line, H4-II-E c3 and the human hepatocyte carcinoma cell line, HepG2 using specific antibodies. Following seeding into 96-well plates cells were treated with either the known CYP1A1 inducer TCDD (10 nM) or vehicle control (0.1% DMSO) for 24 h to allow reproducibly detectable quantities of CYP1A1 to be expressed. Cells were then fixed and immunostained for CYP1A1 followed by the appropriate fluorescent-labeled secondary antibody (Alexa 647) and the nucleic acid binding fluoro-dye Hoechst. In both H4-II-E c3 and HepG2 cells the vehicle control showed low levels of CYP1A1 staining, while a large increase in staining was observed in cells treated with 10 nM TCDD. The optimal antibody concentrations were then assessed using antibody titration experiments. For the rat Cyp1A1 antibody the optimal concentration (lowest concentration to show a statistically detectable signal over background) was determined to be a 1:3000 ( Figure 1A ) dilution from stock and 1:500 ( Figure 1B ) dilution from stock for the human CYP1A1/2 antibody. 
Optimization of Initial Cell Seeding Density
Previous reports in the literature suggest that low cell density can increase the basal expression of CYP1A1 in the HaCaT cell line by influencing the cellular distribution of the AHR (Ikuta et al., 2004) . To establish whether this observation was relevant in this experimental model both H4-II-E c3 and HepG2 cells were seeded at different densities before treatment with vehicle or 10 nM TCDD. In the H4-II-E c3 cells increased cell confluence (20 000 and 30 000 cells vs 10 000) resulted in a reduction in the basal expression of Cyp1A1 protein (Figs. 2A and C, left) and consequent increase in signal window. Z' values per condition were 0.14, 0.67, and 0.61 for the 10, 20, and 30 k cells/well conditions respectively, with Z' value > 0.5 deemed acceptable. Conversely, no significant differences were seen in the signal window in the HepG2 cells at any of the tested initial seeding densities (Figs. 2B and C, right) . Therefore, a seeding density of 20 000 cells/well was selected for both cell lines to ensure optimal assay window.
Result Reproducibility
Using the optimized cell seeding and antibody concentrations the reproducibility of the assay window was assessed over 3 separate assay occasions (days) for each cell line. TCDD (10 nM) was selected as the positive control or maximum condition and 0.1% DMSO as the negative control or minimum signal. Cells were dosed to include a plate treated with 10 nM TCDD (max plate), a plate treated with TCDD and 0.1% DMSO in alternate wells (max-min) and a plate with 0.1% DMSO and TCDD in alternate wells (min-max). Cells were seeded at 20 000 cells/well for 24 h prior to 24 h treatment with either vehicle or 10 nM TCDD. Cells were fixed, stained and imaged. Images were analysed as described earlier with the percentage of positive cells being reported. The results of the assay are summarized in Table 1 . For the H4-II-E c3 cell line (A) the mean Z' value across the 3 separate assay occasions was 0.62 with a mean CV of 10.9%, and for the HepG2 cell line (B) mean Z' value across the 3 separate assay occasions was 0.32 with a mean CV of 10.9%.
The plate maps used in the reproducibility study allow the detection of various methodological inter-and intra-plate effects; for example edge effects can increase assay variability. The results from the Max plates show that the mean of any row or column did not differ by more than 615% of the plate average for either cell line (data not shown).
CYP1A1 Is Controlled by a Switch-like Induction in Rat, but Not Human Cell Line Following optimization of antibody staining conditions a concentration response curve of TCDD (1 Â 10 À13 to 1 Â 10 À8 M) was added to both the H4-II-E c3 and HepG2 cell lines as described above. Cellular analysis demonstrated that the established signal window at higher magnification (20Â, Figure 3A ; images of rat upper, human lower) was maintained at lower (10Â, Figs. 3B and C) imaging magnification, allowing larger population sampling. For the rat H4-II-E c3 cells the staining pattern shows heterogeneity within the population of each well, where adjacent cells can have very different levels of Cyp1A1 staining, and this is maintained across the TCDD concentration range ( Figure 3B ). This is consistent with previous reports of a switch-like pattern of Cyp1A1 induction in both H4-II-E cells and primary rat hepatocytes (Broccardo et al., , 2005 Chubb et al., 2004) . Switchlike rodent induction is exemplified by visualization ( Figure 3D ) of the proportion of individual cellular intensities across the TCDD concentration-response between the 2 species. In contrast the staining pattern in human HepG2 cells across the TCDD concentration range showed considerably less heterogeneity, with adjacent cells becoming progressively brighter (increased staining) in response to increasing concentrations of TCDD ( Figure 3C ). Human HepG2 cells continue to increase in both general brightness and statistical proportion of activated cells with increasing TCDD concentration ( Figure 3D , note top 10 nM TCDD concentration response reduction is coincident with slight overall reduction in cell viability), whereas rat H4-II-E cells increase in general brightness with increasing TCDD concentration but describe a plateau whereby no more than 40% of the cell population can be activated by any concentration of TCDD. This is consistent with previous observations of switchlike induction of rodent AHR.
Reference Compound Testing Dose-concentration response curves were generated for the gold standard AHR activator/CYP1A1 inducer TCDD (1 Â 10 À13 to 1 Â 10 À8 M) and the PXR activator/CYP3A inducer, Pregnenolonecarbonitrile (PCN) (1 Â 10 À9 to 1 Â 10 À4 M). As expected treatment with TCDD increased the amount of CYP1A1 protein present in both cell types in a concentration dependent manner, producing an EC 50 value of 5 qM in H4-II-E c3 ( Figure 4A ) and 167 qM in HepG2 ( Figure 4B ). In both cases PCN failed to cause a significant increase in CYP1A1 protein compared with 10 nM TCDD (Table 2) even at >1000-fold higher concentrations, thereby demonstrating the specificity of the assay for known CYP1A1 inducers.
Further validation for both assays was conducted using compounds identified from the literature that have known effects on CYP1A1 induction in either rat (Table 3) or human (Table 4) systems. The species selectivity of AHR agonists prevented the compound validation sets tested for the rat and human assay from being identical, although some overlap was maintained for confirmation. Importantly, the viability of the cells was monitored at each drug concentration using the postfixation nuclear count "cell" number as an approximation. This allowed the elimination of compound concentrations causing nonspecific cytotoxicity from further analysis for CYP1A1 induction potential.
Demonstration of Cyropreservation as an Alternative Cell Source for Screening
Various combinations of standard cryoprotective mixes and freezing methods were tested for each cell line. Viability and recovery post thawing were assessed by Incucyte (Essen Bioscience, Hertfordshire, UK) brightfield microscopy, aiming to achieve the same cell confluence at compound treatment as with fresh continuously cultured cells seeded at 20 000 cells/ well for 24 h. Similar recovery was shown for a variety of conditions tested (data not shown), and a cryopreservation method using a solution containing 7.5% DMSO in a 50/50 mix of FCS and RPMI 1640 media and freezing using a controlled rate freezer was identified as optimal.
For concordance testing cryopreserved cells were rapidly thawed, washed by centrifugation to remove cryoprotectants, and seeded at either 10 000 (H4-II-E c3) or 5000 (HepG2) cells/ well for 72 h prior to the 24 h compound treatment. Earlier time points were also tested but resulted in increased or less consistent assay backgrounds (data not shown). Performance within the assays was then tested in comparison to fresh continuously cultured cells using the conditions previously described. A subset of previously tested compounds (including the Reference Table) . Cell morphology was assessed by eye and also considered comparable between methods (data not shown). Furthermore positive responders' proportion average for control wells was comparable between methods, and previous measures of reproducibility (Z' and % CV, data not shown) were maintained, indicating that the cryopreservation process does not apparently affect the underlying biology of the assay. This enabled the switch to use of cryopreserved cells using the conditions described above for all subsequent work.
Species Selectivity and the Lack of Rat:Human Correlation in a Drug Discovery Project
Retrospective analysis of compounds profiled through both the rat and human assays was undertaken to compare species differences and sensitivity. 520 compounds from an internal drug discovery project where AHR activation had been suggested in preclinical species by ex vivo RT-PCR were collated ( Figure 6A ) to evaluate the number of compounds that fell into each category of response caused in each species. This analysis showed that 39% of all compounds were active above background at any concentration in the rat assay but nonactive in the human assay, whereas only 3% of compounds showed activity in the human assay without corresponding activity in the rat assay. This suggests that for a set of similar small molecule compounds containing known AHR activation liabilities the rat hepatoma cells were more sensitive to induction of Cyp1A1 than the human cells. It was observed that only 37% of compounds were nonactive and 21% were active for both species. Furthermore, correlation between the EC 50 values (n ¼ 168 valid in both assays) in the human and rat assays was poor ( Figure 6B ) with a Spearman's rank correlation coefficient of 0.24. Figure 6 displays compound data from a drug discovery project where potential AHR activation had been highlighted preclinically. To achieve a broader context we also determined AHR activity rates within more general drug discovery chemistry. We tested 4453 other novel chemistries from the internal AstraZeneca compound collection to determine hit rates within a broader assortment of late drug discovery projects ( Figure 7) . 2% of all compounds tested produced uninterpretable results in either method, frequently associated with precipitation of compound stocks or dilutions, and these data have been excluded from further analysis. The rat assay had a single occasion hit rate of 21% and the human assay 8% (Figure 7, upper) . Analysis of hits indicated continued sensitivity of the rat cells with 17% of all compounds active only in the rat assay while again only 4% were active only in the human assay. Additionally the rate of dual cross assay activity was 4% ( Figure  7 , lower), and three quarters of compounds tested were negative in both assays. Similar hit rates and proportions have thus far been maintained over a period of ten years on regular testing. Amongst those subset of compounds with more statistically relevant repeated test results (valid n ! 2 in both assays) actives were obviously more represented, due to active confirmation re-testing, now with 10% demonstrating dual cross assay activity in both species, while only 12% were active above background at any concentration in the rat assay but nonactive in the human assay. A consistent 3% were still active in the human assay but nonactive in the rat assay, and the proportion of compounds negative in both assays was maintained at three quarters of all samples tested. Within broader general chemistry <2% of all compounds tested had sufficient potency to generate an EC 50 , but of these "Potent" chemistries the majority (two thirds, representing 2% of all compounds tested) were active in both species and showed a similar rat:human potency shift to that observed with TCDD and the previous project data (rat approximately 10-fold more potent than human, data not shown), while proportionally fewer showed species selectivity (29% only active in rat, 6% only active in human, representing < 1% of all tests). Of these only 38 compounds had repeated valid data, and these numbers are insufficient for further meaningful statistical analysis of trends.
Analysis of Hit Rate Within Broader Early Drug Discovery Chemistry
Finally potency of active hits within general chemistry could be used for human chemical risk assessment when handling unknown pharmaceuticals. Much less than 1% of chemistries tested had potentially higher risk (sub-micromolar) potencies (14 compounds in rat and 11 in human respectively). The most potent chemistries observed had activities in the range of 20-50 gM range in both species.
DISCUSSION
We have demonstrated that medium throughput screening for AHR activators can be achieved by monitoring the induction of hepatic cellular CYP1A1 protein levels using an automated, imaging-based approach. The use of specific antibodies allows the detection and quantification of CYP1A1 protein from rat and human hepatic cell lines using bespoke imaging algorithms. Early validation of this imaging-based approach revealed differences in the potential regulation of CYP1A1 expression between the 2 species, as a clear switch-like induction was observed in the rat hepatoma cell line, H4-II-E c3, which was absent in the human cell line counterpart, HepG2. This switchlike induction in the rat system has been previously observed in cell lines as well as in primary hepatocytes and liver slices and may reflect the presence of an enhancer element within the rat Cyp1A1 promoter, demonstrating the retention of correct transcriptional regulation in the immortalized rat cell line used in this assay (Broccardo et al., , 2005 Chubb et al., 2004) . Authentic endogenous signaling ensures higher relevance of a model system. The effect of seeding density on the basal expression of Cyp1A1 protein was also specific to the rat cell line, where cell seeding at low density led to an increase in the number of positive cells seen in the vehicle treated condition. The effect of low seeding density has been linked to the nuclear localization of the AHR itself within the cell of the HaCaT cell line (Ikuta et al., 2004) . It was determined that rodent hepatoma cells may exhibit the same phenomena seen in HaCaT keratinocytes, whereas human hepatic carcinoma cells appear less affected by low seeding density. Further work is needed to clarify if the CYP1A induction pattern or lack of expression changes with cell seeding density seen in the HepG2 cell line is a consequence of the species, or the cell line itself. In both cell lines the magnitude of the signal window was shown to be reproducible over several repeat experiments, and gave a sufficient graduation between the positive and negative controls such that the response to TCDD showed a concentration-dependent increase in the amount of CYP1A1 protein produced in both the rat and human cell lines.
The human antibody can also detect CYP1A2 but inducible expression in HepG2 cells is at low enough levels to remain below assay background and prevent misidentification. Active rat cells were much (> 3-fold) brighter than active human cells, and inactive rat cells more consistently dim, resulting in a larger stable assay signal window and better Z'. However the available cell population in rat which could be activated by TCDD was actually lower (approximately 40% Figure 3D ) than with human cells (>80% Figure 3D , up to 98% Figure 2B ). This is possibly related to the previously observed switch-like induction mechanism in rodent cells and could be an adaption to mitigate organ level repercussions of activation of the greatly more sensitive rodent AHR. The use of high content imaging methodology proved critical in this respect as this technology is easily able to differentiate and quantify these consistent but (at population level) relatively small changes. This should also enable discrimination of compounds nonspecifically affecting general protein turnover, and with further work could establish a TCDD-like induction cellular phenotype to enhance risk classification. Furthermore use of high content multiplexing to also provide additional information on nuclear counts allowed discrimination and exclusion of generic cytotoxic events, something which is critical for assessments in a broader drug discovery context where non-AHR specific antiproliferative and antioncogenic modalities are more common than in traditional toxicity testing chemistries.
Successful use of cryopreserved HepG2 and H4-II-E c3 cell lines has decreased reliance upon continuous cell culture and increased the flexibility of screening occasions, while additionally having the potential to avoid the variable assay performance that can be associated with cellular changes over time in continuous culture (Wigglesworth et al., 2008) . Concordance testing with internal active and reference compounds was able to demonstrate that with a seeding density optimized to allow sufficient recovery time (72 h) without over-confluence, testing of the sensitive AHR activation pathway could be undertaken directly from cyropreserved cell stocks. This method facilitates a more flexible testing paradigm, more in tune with the requirements of early drug discovery where the volume of chemistries requiring assessment can vary significantly over a short time frame.
The necessity of having a dual rat and human assay was exemplified by both the difference in sensitivity the two cell systems showed to common agonists (Tables 2 and 3) , and by the poor cross-species correlation of both actives and inactives found in internal project chemistry ( Figure 6B ).
Previous studies that compared CYP1A1 induction in mammalian cells suggest that humans are less sensitive than rats to TCDD. A study by Lipp et al. (1992) measured TCDD-induced 7-ethoxyresorufin-O-deethylase (EROD) activity in the human HepG2 cell line, while a study by Schrenk et al. (1995) , measured EROD activity in primary human hepatocytes. Comparison of EC 50 s from these studies along with studies from HepG2 and H4-II-E c3 cells (Silkworth et al., 2005; Westerink et al., 2008) , showed that human cells were 1-2 log units less sensitive than rat cells to TCDD and its analogues. Studies such as this show that differences in susceptibility and sensitivity span several orders of magnitude. In this study the potency shift in EC 50 between the 1 systems was consistently between 1 and 1.5 log units over the conditions tested, with TCDD more potent in rat than human. Over a decade of continuous testing the TCDD EC 50 has stabilized at 32 qM in H4-II-E c3 and 359 qM in HepG2 (n > 1000 each), with the rat cells an average of 11-fold more sensitive than human.
Importantly however, the shift in EC 50 between species was not predictably consistent between chemistries. In chemistries from a drug project with suspected rodent AHR activation liability the relative potency shifts in rat:human EC 50 form a distribution ranging from no shift up to more than 2 log units of concentration more potent in rat, somewhat greater than would be expected from interassay variability alone. Although the consistent direction of these potency shifts indicates that the rodent cell system has additional sensitivity for AHR ligands other than TCDD, the breadth of the possible potency shift range complicates any recommendation to use the rodent model as a surrogate for potential human activity. Conversely, a positive result in man well predicts a rodent response to the same compound. The exceptions to this are an oddly consistent 3 to 4% of tested compounds which gave a positive result in the HepG2 assay and a negative result in the H4-II-E assay irrelevant of the source of the chemistries. As such these may represent a form of assay false positive. These compounds warrant further investigation in more physiologically relevant assay systems to verify their human-specific activity, as excluding them would allow us to conclude that all human active chemistries were also active in rodent at some concentration.
By indicating species selectivity using endogenous pathways this dual assay may provide a better method for assessment of relative risk than more artificial reporter-based systems (Hu et al., 2007; Yueh et al., 2005) . The differences in AHR ligand specificity and sensitivity between human and rodent systems has long made it difficult to accurately predict liability in man from positive results in either a rodent in vitro or in vivo assays (and vice versa). Therefore, the assessment of the ability of a compound to activate both rat and human AHR should be assessed preclinically to reduce toxicological liability in drug project chemistry; both that from dose-limiting toxicities in preclinical species and the more serious clinical liability. Since the introduction of these assays there have been no repeats of the activity within chemical series seen with the initial drug project which presented suspected rodent AHR activation liability; where projects have encountered activating chemistries during drug discovery they have been able to deprioritize these in favour of nonactivating chemistries. Although it has been argued that this is an excessively conservative approach (Ehrlich and Kerkvliet, 2017) , it has thus far allowed unobstructed internal progression, and has yet to be truly challenged by a target lacking alternative nonactivating chemistries.
It is important to note that CYP1A1 upregulation is not a perfect biomarker for TCDD-like toxicity, as many compounds that induce this CYP isoform do not carry a toxicological liability, and indeed some inducers do not seem to activate the AHR itself (Delescluse et al., 2000; Hu et al., 2007) or might function solely via noncanonical AHR mechanisms. There is also increasing evidence that weak or partial AHR agonists may have untapped potential in oncology and autoimmune settings (Murray et al., 2010; Safe et al., 2017) , making their deselection positively undesirable, although regulatory practise has yet to fully embrace this opportunity. Practically this assay is also limited in its current format as the 24 h incubation period may be unsuitable for testing metabolically unstable chemistries, and in their current format the assays do not assess the persistence of AHR activation which is considered to be an important part of the manifestation of toxicities following AHR activation (Mitchell et al., 2006) . Our results show that a small number of compounds with potentially physiologically relevant nanomolar potencies are indeed present within a typical pharmaceutical compound library, and given previous evidence for TCDD-like toxicity of such potent AHR activators these must still be considered potentially hazardous. Following hazard identification efforts to reduce these strong effects on CYP1A1 upregulation can then be made by medicinal chemists using an SAR approach. Despite significant efforts over recent years by several groups there remains the need for a complete structure of the AHR protein to facilitate improved in silico modeling and simulation in this regard. There is increasing evidence to suggest that weak or transient AHR activators may not pose any risk of TCDD-like toxicities (Denison and Faber, 2017) , but until clinical evidence emerges to support this regulators will remain cautious.
If significant potent human AHR activation is detected in vitro or evidence for systemic AHR-mediated toxicity is provided by the rodent toxicology studies, it remains advisable to remove this activity from drug project chemical series. To achieve this, the described dual rat and human AHR activation assay should be included in follow-up drug project screening cascades with the aim to influence the chemical design process so that human AHR activation is removed from, or at least identified and minimized within, chemical series progressing into drug development.
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